Abstract:Peptic ulcers, recognized for their erosive impact on the gastrointestinal mucosa, present a considerable challenge in gastroenterology. Epidemiological insights underscore the global prevalence of peptic ulcers, affecting 5–10+% of individuals, with a yearly incidence of 0.3 to 1.9 cases per thousand. Recent decades have witnessed a decline in complications, attributed to improved diagnostics and therapeutic advancements. The review deepens into H. pylori -associated and NSAID-induced ulcers, emphasizing their distinct prevalence in developing and industrialized nations, respectively. Despite advancements, managing peptic ulcers remains challenging, notably in H. pylori -infected individuals facing recurrence and the rise of antibiotic resistance. The pathophysiology unravels the delicate balance between protective and destructive factors, including the intricate molecular mechanisms involving inflammatory mediators such as TNF-α, ILs, and prostaglandins. Genetic and ethnic factors, rare contributors, and recent molecular insights further enhance our understanding of peptic ulcer development. Diagnostic approaches are pivotal, with upper gastrointestinal endoscopy standing as the gold standard. Current treatment strategies focus on H. pylori eradication, NSAID discontinuation, and proton pump inhibitors. Surgical options become imperative for refractory cases, emphasizing a comprehensive approach. Advances include tailored H. pylori regimens, the emergence of vonoprazan, and ongoing vaccine development. Challenges persist, primarily in antibiotic resistance, side effects of acid suppressants, and translating natural compounds into standardized therapies. Promising avenues include the potential H. pylori vaccine and the exploration of natural compounds, with monoterpenes showing therapeutic promise. This review serves as a compass, guiding healthcare professionals, researchers, and policymakers through the intricate landscape of peptic ulcer management. Received: 21 December 2023 Accepted: 16 January 2024 Article published online: 11 March 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany

The clinical application of antipeptie ulcer drugs and its new progress in the treatment

Recent Progress in Research on Proton Pump Inhibitors

Research Advances in Antiulcer Effect of Traditional Chinese Medicines and its Effective Components

Research Progress and Clinical Use of Proton Pump Inhibitors

Helicobacter Pylori Infection: A Recent Approach to Diagnosis and Management

The Update of Pathogenesis and Treatment for Peptic Ulcer

Efficacy of Esomeprazole in Combination with Levofloxacin and Amoxicillin in Treatment of Helicobacter Pylori-Associated Duodenal Ulcer

Pantoprazole effectively treats Helicobacter pylori - associated duodenal ulcer

Clinical Application of Proton Pump Inhibitors

The current views focused on clinical application of proton pump inhibitors

Recent progress in Helicobacter pylori treatment

Recent Advances in Molecular Pathways and Therapeutic Implications for Peptic Ulcer Management: A Comprehensive Review

Progress of diagnosis and treatment schemes of Helicobacter pylori infection

Analysis of the Use of Antiacids and Other Drugs for Peptic Ulcer in Nanjing During the Period 1996～2002

Research Progress on Omeprazole in the Treatment of Peptic Ulcers

The status and progress of first-line treatment against Helicobacter pylori infection: a review

Turn over the new leaf of the treatment in peptic ulcer bleeding: a review of the literature

The research progress of gastric mucosal protective drugs

Treatment of Helicobacter pylori infection——current challenges

The high-dose amoxicillin-proton pump inhibitor dual therapy in eradication of Helicobacter pylori infection

A review on the research progress on non-pharmacological therapy of Helicobacter pylori